South Rampart Pharma Publishes SRP-001's Unique Pain Relief Mechanism and Phase 1 Trial Results in Scientific Reports SRP-001 is a novel, non-opioid new chemical entity without abuse, liver, and kidney toxicities present in current pain medications Publication introduces SRP-001 as a safer alternative to existing...

South Rampart Pharma Receives $1.9 Million NIH Fast-Track STTR Commercialization Grant to Advance its New Class of Non-Opioid Pain Medicines NEW ORLEANS, Sept. 29, 2020 (GLOBE NEWSWIRE) -- South Rampart Pharma, a company committed to improving the lives of people suffering from pain by developing a new class of non-opioid pain medicines,...

South Rampart Pharma Identifies New Class of Non-Opioid Pain Medicines in European Journal of Medicinal Chemistry Publication NEW ORLEANS, July 14, 2020 (GLOBE NEWSWIRE) -- South Rampart Pharma, LLC ("South Rampart" or "the Company"), a company committed to improving the lives of people suffering from pain by developing a...